The beta-2 adrenergic receptor in human BAT
- Conditions
- Obesity, cardiovascular diseases
- Registration Number
- NL-OMON27924
- Lead Sponsor
- A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
Dutch white Caucasian males
- Age between 18-35 years old
- Lean (BMI = 18 and = 25 kg/m2)
- Diabetes mellitus (determined on basis of fasting glucose levels defined by ADA criteria)
- Any other active endocrine disease (thyroid disease, any signs of Cushing’s syndrome, adrenal disease and lipid-associated disorders such as familial hypercholesterolemia)
- Any cardiac disease (i.e. ischemic cardiac disease, arrhythmias, severe heart failure)
- A first-degree family member with sudden cardiac death
- Any chronic renal or hepatic disease
- Use of beta-adrenergic receptor agonists (for e.g. asthma)
- Use of medication known to influence glucose and/or lipid metabolism or brown fat activity (e.g. beta-blockers, antidepressants, corticosteroids)
- Use of medication shown to increase risk on hypokalemia after salbutamol administration (e.g. xanthine derivatives, steroids and diuretics)
- Any other contra-indications for the use of salbutamol or propranolol
- Abuse of alcohol or other substances
- Smoking
- Participation in an intensive weight-loss program or vigorous exercise program during the last year before the start of the study
- Current participation in another research projects that may influence the current research project
- Participation in another research with exposure to radiation burden within a year before the start of the current study
- Clinically relevant abnormalities in clinical chemistry or electrocardiogram (ECG) at screening (to be judged by the study physician)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Glucose uptake by BAT, as measured by dynamic [18F]FDG PET/CT acquisition
- Secondary Outcome Measures
Name Time Method - Resting energy expenditure, as measured by indirect calorimetry<br>- Serum markers for lipid metabolism (triglycerides (TG), total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), free fatty acids)<br>- Lipid pathway analysis using lipidomic analysis in plasma samples<br>- Serum markers for glucose metabolism (glucose, insulin)<br>- Circulating plasma BAT markers (e.g. microRNAs)